PacBio reported a decrease in total revenue compared to the prior year, primarily driven by lower instrument revenue. However, consumable revenue and service and other revenue saw increases. GAAP net loss significantly widened due to substantial restructuring charges, while non-GAAP net loss slightly improved. The company initiated a restructuring plan to reduce operating expenses and focus on its long-read business.
Total revenue decreased to $37.2 million in Q1 2025 from $38.8 million in Q1 2024.
GAAP net loss was $426.1 million in Q1 2025, compared to $78.2 million in Q1 2024, largely due to restructuring costs.
Non-GAAP net loss was $44.4 million in Q1 2025, an improvement from $71.4 million in Q1 2024.
The company initiated a restructuring plan to reduce annualized non-GAAP operating expenses by approximately $45 million to $50 million by the end of 2025.
PacBio remains cautious due to the current macroeconomic environment, including uncertainty around academic funding and potential trade policy developments. The recent restructuring is intended to navigate near-term challenges while working towards achieving cash flow breakeven exiting 2027.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance